Symptoms of critical limb ischemia include:
The Stem Cells Transplant Institute in Costa Rica, uses adult mesenchymal stem cells for the treatment of critical limb ischemia.
Critical limb ischemia is the most severe form of peripheral artery disease.
Peripheral arterial disease occurs when atherosclerosis, the buildup of plaque, causes a narrowing, or blocking of the blood vessels in the peripheral arteries.
Plaque is caused by the presence of cholesterol, calcium, fat and other substances in the blood.
When plaque builds up in the arteries, they harden and weaken, and can no longer send enough blood flow to the extremities, usually the legs.
Critical limb ischemia is associated with a high risk of amputation, myocardial infarction, and death, with mortality rates of 20% within 6 months of initial diagnosis and 50% at 5-years2.
Risk factors for peripheral artery disease and critical limb ischemia include:
The standard treatment for critical limb ischemia is surgical or endovascular revascularization. Up to 30% of patients do not qualify for treatment because of risks associated with treatment, meaning prognosis for these patients is poor.3
Critical limb ischemia is associated with a poor quality of life and high treatment costs. Stem cell therapy at the Stem Cells Transplant Institute may be a good alternative for patients seeking a safe, non-surgical treatment for critical limb ischemia.
Stem cell transplantation uses healthy cells to promote the repair of damaged cells and regeneration of healthy and functional cells.1
The therapeutic effect of stem cell transplantation in patients with critical limb ischemia may be due to the paracrine effect.
The paracrine effect theory is, transplanted stem cells repair damaged tissue by releasing factors that promote regeneration of healthy stem cells, reduce inflammation, promote the growth of new blood vessels, inhibit cell death, and reduce hypertrophy.1
Animal and human trials have shown stem cell transplantation to be safe and effective in patients with critical limb ischemia.
Research has shown stem cell therapy, in critical limb ischemia, resulted in:3,4
Stem cell therapy cannot help all patients with critical limb ischemia, but for many patients, stem cell therapy, combined with lifestyle modification, may be a safe, effective, non-surgical treatment alternative.
Lifestyle changes that can help improve cardiovascular disease include:1,2
For optimal results, the Stem Cells Transplant Institute recommends the use of hUC-MSCs for the treatment of critical limb ischemia.
If the patient prefers, autologous mesenchymal stem cells derived from the patient’s own adipose tissue and bone marrow, can also be used to treat peripheral artery disease.
Umbilical cord stem cells
We use only umbilical cord stem cells that are derived exclusively from umbilical cord donations.
The umbilical cord stem cells from are collected after informed consent has been given by the parent, or parents, and only after the delivery of the baby.
The collection follows strict ethical protocols ensuring the stem cells are from safe, reliable sources using a non-invasive, simple and painless procedure. Once collected, the cord blood is then screened for disease.
Autologous adipose and bone marrow stem cells
On the day of the procedure, under local anesthesia and sterile conditions, a small sample of bone marrow is removed from the hip and a small of amount of adipose tissue (fat) is removed from the abdomen.
The stem cells are administered intravenously and locally, into the affected limb, by subdermal and intramuscular injection.
Costa Rica has one of the best healthcare systems in world and is ranked among the highest for medical tourism.
Using the most advanced technologies, the team of experts at The Stem Cells Transplant Institute believes in the potential of stem cell therapy for the treatment of critical limb ischemia.
We are committed to providing personalized service and the highest quality of care to every patient.
Contact us to see if stem cell therapy may be a treatment option for you.
1. Sun R.Advances in stem cell therapy for cardiovascular disease (Review). National Journal of Mol. Med. 38: 23-29, 2016
2. Martin Teraa, et. al., Critical Limb Ischemia: Current Trends and Future Directions. J Am Heart Assoc. 2016;5:e002938 doi: 10.1161/JAHA.115.002938.
3. J. Yan, G. Tie, T. Y. Xu, K. Cecchini, and L. M. Messina, “Mesenchymal stem cells as a treatment for peripheral arterial disease: current status and potential impact of type II diabetes on their therapeutic efficacy,” StemCell Reviews and Reports, vol.9, no. 3, pp. 360–372, 2013. 4 Rita Compagna Cell Therapy in Patients with Critical Limb Ischemia Hindawi Publishing Corporation. Stem Cells International. Volume 2015, Article ID 931420, 13 pages